Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: Synergistic or antagonistic?

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 18, 2013, Pages 2457-2462

  Luke, Jason John ^a   Ott, Patrick Alexander ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BRAF; CTLA 4; Immune checkpoint blockade; Immunotherapy; Kinase inhibitors; MEK; Melanoma

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; DASATINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; OXALIPLATIN; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN ANTIBODY; SUNITINIB; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; METASTATIC MELANOMA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY; MAP KINASE KINASE KINASES; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84887891303     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.849244     Document Type: Review

References (24)

1. Agarwala S. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: Cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010;20(1):1-10
2. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366-77
3. Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14:2484-91
4. Kao J, Ko EC, Eisenstein S, et al. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011;77(1):12-9
5. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22
6. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T-And NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116(5):772-82
7. Ray P, Krishnamoorthy N, Oriss TB, et al. Signaling of c-kit in dendritic cells influences adaptive immunity. Ann NY Acad Sci 2010;1183:104-22
8. Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011;17:1094-100
9. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res 2011
10. Khalili JS, Liu S, Rodriguez-Cruz TG, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012;18:5329-40
11. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403
12. Koya RC, Mok S, Otte N, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012;72:3928-37
13. Hong DS, Vence L, Falchook G, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012;18:2326-35
14. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-19
15. Gabrysova L, Christensen JR, Wu X, et al. Integrated T-cell receptor and costimulatory signals determine TGF-beta-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol 2011;41: 1242-8
16. Janardhan SV, Praveen K, Marks R, et al. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One 2011;6:e24931
17. Ott PA, Henry T, Baranda SJ, et al. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 2013;62:811-22
18. Kalland ME, Oberprieler NG, Vang T, et al. T cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J Immunol 2011;187:5233-45
19. Jiang X, Zhou J, Giobbie-Hurder A, et al. The paradoxical activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609
20. Tompers Frederick D, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31
21. Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011;117:758-67
22. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
23. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6
24. Hamid O, Sosman J, Lawrence D, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013;31 (Suppl): Abstract 9010